FDA decisions loom for four biotech firms this week

FDA decisions for CAPR, NRXP, REPL, and MRNA could sharply reshape valuations overnight.

CAPR faces a PDUFA date for its gene therapy for Duchenne muscular dystrophy.

NRXP awaits FDA verdict on its antidepressant for treatment-resistant depression.

REPL seeks clearance for its treatment of a rare genetic disorder.

MRNA's RSV vaccine candidate is under FDA review for older adults.